DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC) had its target price increased by HC Wainwright from $7.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 91.94% from the company’s current price.

DiaMedica Therapeutics Stock Down 13.0 %

DMAC stock opened at $5.21 on Wednesday. DiaMedica Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $6.82. The firm’s 50-day simple moving average is $5.95 and its 200 day simple moving average is $5.10. The stock has a market cap of $222.78 million, a PE ratio of -9.30 and a beta of 1.52.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Equities analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several large investors have recently bought and sold shares of DMAC. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $40,000. Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Blue Trust Inc. grew its stake in shares of DiaMedica Therapeutics by 56.2% in the 4th quarter. Blue Trust Inc. now owns 69,122 shares of the company’s stock worth $375,000 after purchasing an additional 24,875 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of DiaMedica Therapeutics in the 4th quarter worth approximately $81,000. Finally, Meridian Wealth Management LLC acquired a new position in shares of DiaMedica Therapeutics in the fourth quarter worth about $148,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.